Logo

Seattle Genetics Reports Multiple Results of Adcetris (Brentuximab Vedotin) in P-III ECHELON-1- P-I/II- P-II and P-III AETHERA study in Patients with Hodgkin Lymphoma at ISHL 2018

Share this

Seattle Genetics Reports Multiple Results of Adcetris (Brentuximab Vedotin) in P-III ECHELON-1- P-I/II- P-II and P-III AETHERA study in Patients with Hodgkin Lymphoma at ISHL 2018

Shots:
  • The Multiple Studies P-III ECHELON-1 (Adcetris + CT vs CT)- P-I/II & P-II (Adcetris + Opdivo(nivolumab)) and P-III AETHERA (Adcetris) is evaluated in patients with stage III or IV HL- r/r HL and HL at Risk of Relapse or Progression respectively
  • Results of P-III ECHELON-1: superior PFS with safety and efficacy: P-I/II & P-II: objective response- CR- PR (80%-82%; 61%- 55%; 20%-27%); OS & PFS (95%- 82%); IRR 36%: P-III AETHERA study: PFS rate (59% vs 41%); received anti-cancer therapy (32% vs 54%); allogeneic stem-cell transplants (17% vs 31%)
  • Adcetris is a ADC directed for CD30 and is currently evaluated in > 50 ongoing trials for HL. In 2018- Adcetris + CT received the US FDA approval for Stage III or IV HL in adults
/ article | Ref: Seattle Genetics | Image: The Street

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions